Showing posts with label pfizer. Show all posts
Showing posts with label pfizer. Show all posts

AMPLIFY-EXT trial of Eliquis(Apixaban) shows positive results



AMPLIFY -EXT trial of Eliquis(Apixaban)shows positive results in phase3 trial. This trial evaluated clinical and demographic predictors of all cause hospitalization in patients suffering from VTE,which include DVT and PE.DVT stands for Deep vein thrombosis and PE stands for Pulmonary embolism .
  This Phase 3 trial included randomized ,double blinded,placebo controlled , extended treatment (AMPLIFY-EXT) for 12 months .
 Out of 2486 total patients,138 patients were hospitalized during this AMPLIFY-EXT trial at least once.
      With this 12 month extended treatment of VTE ,and its positive results provides additional support for extended anti coagulation support with Eliquis(Apixaban) in VTE patients .
BMS and Pfizer are the developers of this Eliquis drug. 

Xalkori and Pemrolizumab comination to be explored in Lung cancer(NSCLC)

Xalkori(crizotinib) of Pfizer and Pemrolizumab of Merck combination dug potential to be explored in phase 1 clinical study in which the Safety and Tolerability  of this combination in patients with ALK+  advanced or metastatic non -small cell lung cancer (NSCLC) is to to evaluated.
                  Individually , Crizotininb(Xalkori) inhibits an abnormally activated enzyme in patients with ALK+ metastatic lung cancer , and pembrolizumab (investigational drug) harnesses body immune system to fight Cancer. Permbrolizumab exerts dual ligand blockade of Programmed cell death protein 1(PD-1) on T lymphocytes(T-cells) with its ligands PD-L1 and PD-L2.

Depo-Medol(methylprednisolone acetate) ,of Pfizer recalled after it fails pH testing

Depo-Medrol(methylprednisolone acetate ) ,manufactured by Pfizer has to recall 94,000 vials of 40mg/ml single dose vials as they failed pH  specification testing at months where  the result obtained was 2.9  contrary to registered specification  pH 3.0 -7.0.They are recalled voluntarily nation wide.